Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Zapping away AFib: first human test of new ablation device begins

NCT ID NCT06452589

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tests a new device called the FieldForce Ablation System in 35 people with atrial fibrillation (AFib). The device uses short electrical pulses to destroy tiny areas of heart tissue causing the irregular rhythm. The main goals are to see if it is safe and if it can successfully isolate the pulmonary veins, a key step in treating AFib.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
FieldForce Ablation System (pulsed field ablation device)
What this could lead to
If successful, this could provide a new, safer option for treating atrial fibrillation by using targeted electrical pulses to correct heart rhythm.
What could go wrong
This is a very early, first-in-human trial with only 35 people. The device may not work as expected or could cause side effects like heart rhythm problems or blood clots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

35 people

The number who actually took part.

Started

Jul 2024

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Signed patient informed consent form (ICF). 2. Female and male patients aged ≥ 18 and ≤ 80. 3. Documented atrial fibrillation via an electrocardiogram (must be at least 30 seconds) within one year of enrollment. 4. Indicated for a first-time catheter ablation for atrial fibrillation or associated atrial arrhythmias (European guidelines). Exclusion Criteria: 1. Body Mass Index \> 40. 2. Ineligible for ablation (including but not limited to known left atrial thrombus). 3. AF secondary to electrolyte imbalance, thyroid disease, alcohol abuse or other reversible/non-cardiac causes. 4. Previous endocardial/epicardial ablation or surgery for AF. 5. NYHA Class IV. 6. Left atrial appendage device or occlusion within 180 days. 7. Atrial or ventricular septal defect closure. 8. Atrial myxoma. 9. The presence of inferior vena cava embolic protection filter devices. 10. Significant or symptomatic untreated hypotension, bradycardia, or chronotropic incompetence. 11. History of hemodynamically severe valvular disease. Severity should be assessed using echocardiography, according to AHA and European guidelines. 12. Diagnosis of pacemaker dependance. 13. Uncontrolled abnormal bleeding and/or clotting disorder. 14. Contraindication to systemic or oral anticoagulation. 15. Serious or untreated medical conditions that would prevent participation in the study, interfere with assessment of therapy, or confound data or its interpretation, including but not limited to solid organ or hematologic transplant, or currently being evaluated for an organ transplant. 16. History of severe lung disease, pulmonary hypertension, or any lung disease involving abnormal blood gases or significant dyspnea which may interfere with the assessment of the therapy. 17. Active malignancy. 18. Uncontrolled clinically significant infection. 19. Life expectancy is less than one year. 20. Clinically significant psychological condition that in the investigator's opinion would prohibit the subject's ability to meet the study requirements. 21. Any of the following within 3 months of enrollment: myocardial infarction, unstable angina, percutaneous coronary intervention, heart surgery (coronary artery bypass grafting/atriotomy), stroke or transient ischemic attack (TIA); 22. Participation in another investigational study that would interfere with this study. 23. Patient is not able to understand the nature of this study or is unwilling or unable to attend the study procedures. 24. Women who are of childbearing age and not on a reliable form of birth control.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial arrhythmias are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Na Homolce Hospital

    Prague, 150 00, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.